Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

CLASS II -- SCANDONEST 3% PLAIN (MEPIVACAINE HYDROCHLORIDE) INJECTION USP, a dental anesthetic in cartridges packed in vacuum cans, 50 cartridges per can. Recall number: D-322-3. Lot number 2B3138 EXP 6/95. Manufacturer: Specialities Sepodont, Paris, France. Recalled by: Deproco, Inc., New Castle, Delaware, by telephone August 9 and 10, 1993, followed by letter August 11, 1993. Firm-initiated recall ongoing. Distribution: Nationwide; 142,000 cartridges were distributed. Reason: Some cans labeled Scandonest Cartridges contained Isocaine 2% cartridges. CLASS III -- (A) ETHER, USP; (B) ETHER FOR ANESTHESIA, USP Recall number: D-319/320-3. Lot numbers and sizes: (a) D45626 - 1 L., 4 L., 320 lbs; F39638 - 4 L.; G10601, G22655, G27659 - 1 L., 4 L.; (b) D45629 - 250 ml, 1 L.; D50631 - 250 ml; E16604 - 150 ml, 250 ml, 1 L; E28605 - 250 ml, 1 L, E38640 - 1 L, E45633 - 150 ml, 250 ml, 1 L; E51627 - 150 ml, 250 ml, 1 L; F03623 - 150 ml, 250 ml, 1 L, F39641 - 150 ml, 250 ml, 1 L; F52610 - 150 ml, G05648 - 1 L, G10604 - 1 L, G22658 - 150 ml, 150 ml, 1 L; Ethyl Ether for Anesthesia, Fisher label: 905778 - 150 ml, 1 L, 905790 - 150 ml, 1 L; 912843 - 150 ml, 1 L, 913432 - 1 L, 913819 - 150 ml, 1 L; 914018 - 150 ml, 1 L, 915663 - 150 ml, 1 L, 920052 - 1 L, 922858 - 150 ml, 1 L, 922860 - 150 ml, 1 L, 923072 - 150 ml, 925548 - 150 ml, 925549 - 150 ml; 925550 - 150 ml. Under the labels J. T. Baker and Fisher Scientific. Manufacturer: J. T. Baker, Inc., Jackson, Tennessee (repacker/responsible firm). Recalled by: J. T. Baker, Inc., Phillipsburg, New Jersey, by letter August 6, 1993. Firm-initiated recall ongoing. Distribution: Nationwide, international; (a) 415 packages (all sizes); (b) 7,566 packags (all sizes) remained in commerce at the time of recall initiation. Reason: Products do not meet USP peroxide specification. CLASS III -- ENTERIC-COATED ASPIRIN TABLETS 325 mg, (5 gr) in 100, 200, and 1000 size bottles, under the following labels: J. J. Balan, C. S. Ruckstuhl Co., Inc., Reyman Drug Co., Inc. Recall number: D-321-3. Lot numbers: IB-1021 EXP 2/94, HF-1045 EXP 6/93, HD-1033 EXP 4/93, HD-1032 EXP 4/93, HC-1020 EXP 3/93. Manufacturer: Royce Laboratories, Inc., Miami, Florida. Recalled by: Manufacturer, by letter February 23, 1993. Firm- initiated recall complete. Distribution: Nationwide and Puerto Rico; 2,000,000 tablets from each lot were distributed. Reason: Product does not meet dissolution specification.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts